Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biopharmaceutical

HINJ, PhRMA, Others Challenge NJ Attorney General’s Push to Limit Compensation to Prescribing Doctors

Dean J. Paranicas, President and Chief Executive Officer, HINJ

Trenton, NJ, October 23, 2017 — WHYY Public Radio Philadelphia’s Joe Hernandez reports that, in a new push to fight the opioid crisis, New Jersey officials are trying to stop the flow of legal but highly addictive painkillers at the source: doctors.

A proposed rule change by N.J. Attorney General Christopher Porrino would restrict the amount of money and other compensation drug companies can give out to doctors and other prescribers.  In doing so, state officials hope medical professionals will feel less pressure to prescribe opioids created and sold by the same companies that ply them with gifts and food.

But at a Thursday public hearing in Newark, representatives of the state’s pharmaceutical and medical industries criticized the potential rule change, questioning why it would apply to all drugs and claiming it would damage patient care and drive providers out of state. Continue reading

PhRMA’s Chief Medical Officer on ‘The Next Five Years of PDUFA VI: Driving the Availability of Innovative Treatments for Patients’

Dr. Bill Chin

Washington, DC, October 13, 2017William “Bill” Chin, M.D., who serves as the chief medical officer of Pharmaceutical Research and Manufacturers of America (PhRMA) and leads the Scientific & Regulatory Advocacy department as executive vice president, wrote the following on PhRMA’s blog, The Catalyst, on October 2:

Yesterday, October 1, marked the first day of implementation for PDUFA VI, the next iteration of the Prescription Drug User Fee Act (PDUFA) and one of the best tools that the U.S. Food and Drug Administration (FDA) has for enhancing regulatory efficiency and encouraging innovative development of safe and effective new medicines for patients.

First enacted in 1992, PDUFA allows the FDA to collect user fees from biopharmaceutical companies to help support the agency’s process for review of new drugs and biologics. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, September 26, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

PhRMA’s New ‘Let’s Talk About Cost’ Campaign Convenes National Dialogue on Medicine Costs

Washington, DC, September 23, 2017Robert Zirkelbach, Executive Vice President of Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), in July posted on the association’s blog, The Catalyst:

Discussions about costs are important. We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs.  And we want to help find the answers.

We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs. And we want to help find the answers. Continue reading

Gov. Christie, Pharma Executives and Federal Leaders Discuss Public-Private Partnership to Address Opioid Epidemic

Governor Chris Christie

Trenton, NJ, September 19, 2017 — Governor Chris Christie, chairman of the President’s Commission on Combating Drug Addiction and the Opioid Crisis, yesterday joined Kellyanne Conway, Counselor to the President, and Former U.S. Rep. Patrick Kennedy, a commission member, in a roundtable at the War Memorial with leaders of the pharmaceutical industry, the National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) to advance a public-private partnership that can address America’s epidemic of addiction.

Governor Christie said, “The public and private sectors must join together to address this public health crisis and act quickly to stop an epidemic delivering a death toll equivalent to America enduring another 9-11 attack every two and a half weeks.” Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, September 16, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading

U.N. Report: Over Half of People with HIV Having Treatment for First Time

London, September 15, 2017 — The Associated Press’ Maria Cheng reported in July that, for the first time in the global AIDS epidemic that has spanned four decades and killed 35 million people, more than half of all those infected with HIV are on drugs to treat the virus, the United Nations said in a report released Thursday.

AIDS deaths are also now close to half of what they were in 2005, according to the U.N. AIDS agency, although those figures are based on estimates and not actual counts from countries.

Experts applauded the progress, but questioned if the billions spent in the past two decades should have brought more impressive results. The U.N. report was released in Paris where an AIDS meeting begins this weekend. Continue reading

PhRMA Publishes 2017 Biopharmaceutical Industry Resources; Member Companies Spent $65.5 Billion on R&D in 2016

PhRMA’s 2017 “Chart Pack”

Washington, DC, September 14, 2017 — Did you know that Pharmaceutical Research and Manufacturers of America (PhRMA) member companies invested $65.5 billion in research and development (R&D) in 2016?

Or that combined spending on brand medicines, generics and the supply chain account for 14 percent of total national health spending, with brands accounting for just half of this (7 percent)?

Or that the United States accounts for two thirds of the world’s venture capital investments in high-growth biopharmaceutical startups?

These are but a few of the facts that can be found in PhRMA’s 2017 Biopharmaceutical Research Industry Profile and the 152-page industry chart pack, Biopharmaceuticals in Perspective, which were released July 20.
Continue reading

PhRMA Offers Consumers Online Resources on Biologics and Biosimilars

Washington, DC, September 7, 2017 ― Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available.

A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA.

To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, the Pharmaceutical Research and Manufacturers of America (PhRMA) in March 2016 launched a new section of our website today that provides educational resources on these topics. Continue reading

VENDORS EVENT: Somerset County Business Partnership and HINJ to Host ‘How to Do Business with Pharma and Medtech Companies’ on November 2

Bridgewater, NJ, August 6, 2017 — The Somerset County Business Partnership (SCBP) and the HealthCare Institute of New Jersey (HINJ) will host “How to Do Business with Pharma and Medical Technology Companies” on November 2 from 8:00 to 11:30 a.m. at the Raritan Valley Community College, Route 28 and Lamington Road, North Branch.

New Jersey’s biopharmaceutical and medical technology companies purchase more than $6.5 billion worth of goods and services from thousands of local suppliers across the state.

This purchasing power supports more than 350,000 spin-off jobs throughout the state. Continue reading